{
    "clinical_study": {
        "@rank": "137931", 
        "arm_group": {
            "arm_group_label": "chemotherapy induced nausea and vimiting, FOLFOX, FOLFIRI"
        }, 
        "biospec_descr": {
            "textblock": "blood sampling"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The most common toxicity of chemotherapy is nausea and vomiting, and appropriate management\n      of these toxicities can help patients improve tolerance for chemotherapy. Anti-emetics\n      including dopamine antagonist, serotonin antagonist, and substance P antagonist administered\n      to patients according to emetogenic risk of chemotherapeutic drugs. However, patients don't\n      always experience same nausea and vomiting for the same drugs. Therefore, it is important to\n      determine the biomarker to predict chemotherapy-induced nausea and vomiting. Some biomarkers\n      studies were done during the chemotherapy. However it is not definite evidence of relations\n      between biomarkers and chemotherapy. We will hope to find any predictive biomarker of CINV."
        }, 
        "brief_title": "Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chemotherapy-induced Nausea and Vomiting", 
            "Moderate Emetogenic Chemotherapy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Nausea", 
                "Vomiting"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. Primary Objective To evaluate the role of some predictive biomarkers for\n           chemotherapy-induced nausea and vomiting\n\n        2. Secondary Objective To evaluate the clinical characteristics related to\n           chemotherapy-induced nausea and vomiting in Korean patients\n\n        3. Study design\n\n           Chemotherapy Day Day1 Day3  Day15\n\n           Chemotherapy 1st cycle FOLFOX/ FOLFIRI 2nd cycle FOLFOX/ FOLFIRI Blood Sampling  1st\n           sampling (8 a.m.) 2nd sampling (8 a.m.)  3rd sampling (8 a.m.) Evaluation of nausea and\n           vomiting Patient's Diary (Day 1-4)\n\n        4. Evaluation of chemotherapy-induced nausea and vomiting\n\n             -  Patient's Diary consisting of the following three elements:\n\n                  1. NCI-CTCAE (National cancer institute-common toxicity criteria adverse event)\n                     version 4.0\n\n                  2. 100mm Visual Analog Scale (VAS)\n\n                  3. Functional living index- emesis\n\n             -  Patients should write 'Patient's Diary' from chemotherapy day 1 to chemotherapy\n                day 4.\n\n        5. Evaluation of the serum levels of Biomarkers (substance P et. al.) 1) Blood sampling\n\n             -  Sample 1: 1st cycle, chemotherapy starting day 1, fasting 8 a.m.\n\n             -  Sample 2: 1st cycle, chemotherapy day 3, fasting 8 a.m.\n\n             -  Sample 3: 2nd cycle, chemotherapy starting day 1 (day 15 after 1st cycle\n                chemotherapy), fasting 8 a.m.\n\n                2) ELISA test for biomarkers (Sample 1,2,3)\n\n      5. Visiting Schedule\n\n      Screening Chemotherapy Time of Visit D-3 to -1  1st day of 1st cycle (Day 1) 3rd day of 1st\n      cycle (Day 3) 4th day of 1st cycle (Day4) 1st day of 2nd cycle (Day 15) Inclusion/exclusion\n      criteria x Informed consent x Distribution of patient's diary x Blood sampling  x x  x\n      Return of patient's diary    x\n\n      6. Statistical methods and data analysis Continuous variables, including serum levels of\n      biomarkers, are expressed as median, minimum, and maximum values. Comparisons of continuous\n      variables are made using the Mann-Whitney U test and the Kruskal-Wallis test. The chi-square\n      test is used for comparisons of categorical variables."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Minimum age of 18 years\n\n          -  Histologically proven solid organ cancer\n\n          -  Eastern Cooperative Oncology Group Performance status 0-2\n\n          -  More than 3 months for life expectancy\n\n          -  Patients scheduled to receive the first line, first cycle FOLFOX (5-FU, Oxaliplatin,\n             Leucovorin) or FOLFIRI (5-FU, Irinotecan, Leucovorin) chemotherapy\n\n          -  Patients must sign an informed consent indicating that they are aware of the\n             investigational nature of the study in keeping with the policy of the hospital\n\n        Exclusion Criteria:\n\n          -  Patients who have nausea and vomiting caused by other reasons such as CNS metastases\n             or gastrointestinal                             obstruction\n\n          -  Patients who were exposed previously to any chemotherapy except adjuvant FL (5-FU and\n             leucovorin)\n\n          -  Patients who take anti-emetic drugs or dopamine antagonist within 72 hours prior to\n             administration of chemotherapy\n\n          -  Patients who take other drugs that may affect serum level of biomarkers (ex. steroid,\n             megesterol, hormone replacement therapy, parenteral nutrition)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients scheduled to receive the first line, first cycle FOLFOX (5-FU, Oxaliplatin,\n        Leucovorin) or FOLFIRI (5-FU, Irinotecan, Leucovorin) chemotherapy"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01993381", 
            "org_study_id": "CINV_CUKorea"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "chemotherapy-induced nausea and vomiting", 
        "lastchanged_date": "November 20, 2013", 
        "location": {
            "contact": {
                "last_name": "Byoungyong Shim, Ph.D., M.D", 
                "phone": "82-31-249-8457"
            }, 
            "facility": {
                "address": {
                    "city": "Suwon", 
                    "country": "Korea, Republic of", 
                    "state": "Gyeonggi-do", 
                    "zip": "442-723"
                }, 
                "name": "St. Vincent's Hospital"
            }, 
            "investigator": {
                "last_name": "Byoungyong Shim, M.D., Ph.D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting(CINV)", 
        "overall_official": {
            "affiliation": "Department of medical oncology, The Catholic University of Korea", 
            "last_name": "Byoungyong Shim, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Chemotherapy Day Day1 Day3  Day15\nChemotherapy\nst cycle FOLFOX/ FOLFIRI\nnd cycle FOLFOX/ FOLFIRI Blood Sampling  1st sampling (8 a.m.) 2nd sampling (8 a.m.)  3rd sampling (8 a.m.) Evaluation of nausea and vomiting Patient's Diary (Day 1-4)", 
            "measure": "To evaluate the role of some predictive biomarkers for chemotherapy-induced nausea and vomiting", 
            "safety_issue": "No", 
            "time_frame": "2 weeks after chemotherapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01993381"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The Catholic University of Korea", 
            "investigator_full_name": "Byoungyong Shim", 
            "investigator_title": "Associate professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Patient's Diary consisting of the following three elements:\nNCI-CTCAE (National cancer institute-common toxicity criteria adverse event) version 4.0\n100mm Visual Analog Scale (VAS)\nFunctional living index- emesis\nPatients should write 'Patient's Diary' from chemotherapy day 1 to chemotherapy day 4.\nEvaluate about clinical history of patients", 
            "measure": "To evaluate the clinical characteristics related to chemotherapy-induced nausea and vomiting in Korean patients", 
            "safety_issue": "No", 
            "time_frame": "2 weeks after chemotherapy"
        }, 
        "source": "The Catholic University of Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Catholic University of Korea", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}